Katalog der Deutschen Nationalbibliothek

Go to:

Knowledge Web

Person
Person

Person

Georg Heß (1966-)

Internist

Name

Georg Heß

Time

1966- (Date of birth and death)

Place

Mainz (Geburtsort)
Berlin (Wirkungsort)
Deutschland

Gender

männlich

Profession

Internist (characteristic profession)

Variant

Georg Reinhold Heß
Georg Hess

Related

Klinikum Charlottenburg

Further information

Diss. und Habil. am Fachbereich Medizin der Univ. Mainz; Schwerpunkt Hämatologie/internistische Onkologie; Oberarzt
Ass.-Prof. an der Freien Universität Berlin; Klinikum Charlottenburg; Fachgebiet(e): Innere Medizin

Record type

Person

GND-Identifier

136395384

Record ID

136395384

Involved in

show all

Loncastuximab tesirin beim DLBCL: eine wirksame Option bei fortgeschrittener Therapiesituation

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma

Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma

A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial

Improved efficacy of tafasitamab plus lenalidomide versus systemic therapies for relapsed/refractory DLBCL: RE-MIND2, an observational retrospective matched cohort study

Kinetics of renal function during induction in newly diagnosed multiple myeloma: results of two prospective studies by the German Myeloma Study Group DSMM

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses

Temsirolimus : Einsatz von Temsirolimus beim Mantelzell-Lymphom ; Erfahrungen und Empfehlungen eines Workshops

Der mTOR-Inhibitor Temsirolimus : Wirkprinzip und Ergebnisse beim rezidivierten und/oder refraktären Mantelzell-Lymphom

Bestimmung und therapeutische Beeinflussung minimaler Resterkrankung hämatologischer Systemerkrankungen am Beispiel der chronischen myeloischen Leukämie und der Non-Hodgkin-Lymphome

Struktur und Expression des Erythropoetinrezeptors bei Patienten mit Polycythaemia rubra vera
Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

DNB portal